Department of Otorhinolaryngology, NHC Key Laboratory of Otorhinolaryngology (Shandong University), Qilu Hospital of Shandong University, Jinan, Shandong, China.
Eur Arch Otorhinolaryngol. 2022 Jan;279(1):361-371. doi: 10.1007/s00405-021-06780-y. Epub 2021 Apr 17.
The authors aimed to clarify the optimal treatment strategy and the indication of different treatments in managing advanced laryngeal squamous cell carcinoma (LSCC).
A total of 9700 patients with advanced (T3-4aN0-3M0) LSCC who treated with (1) surgery alone, (2) surgery plus adjuvant radiation with or without chemotherapy (aCRT/RT), or (3) definitive CRT/RT was retrieved from the SEER database. The propensity score matching (PSM) was applied to balance confounding factors. Kaplan-Meier method and Cox proportional hazards regression were used to comparing the overall survival (OS) of patients.
After optimal matching, 907 patients were screened from each treatment cohort. Kaplan-Meier and multivariate analyses presented that patients treated with surgery plus aCRT/CT had significantly longer OS than those treated with either surgery alone or CRT/RT, even after PSM. However, significant interactions were tested in treatment effects in stratified analyses of the primary subsite, T stage, N stage, and insurance status (P < 0.05 for all). Specifically, surgery plus aCRT/CT significantly improved the OS of patients with supraglottic, T4a, and N + tumors (P < 0.001 for all), while three treatment modalities achieved equal OS rates for patients with glottic, T3, and N0 tumors (P > 0.05 for all). Besides, supraglottic tumors presented a poorer prognosis than glottic subsite.
Current study suggests that surgery with aCRT/RT is the preferred initial therapy for patients with T4a tumors, whereas patients with T3 tumors could be treated with either surgery (followed by aCRT/RT if it presents N +) or definitive CRT/RT for achieving laryngeal preservation. More-intense treatment should be emphasized for advanced supraglottic cancer.
作者旨在阐明治疗晚期喉鳞状细胞癌(LSCC)的最佳治疗策略和不同治疗方法的适应证。
从 SEER 数据库中检索了 9700 例接受以下治疗的晚期(T3-4aN0-3M0)LSCC 患者:(1)单纯手术,(2)手术加辅助放疗加或不加化疗(aCRT/RT),或(3)根治性 CRT/RT。应用倾向评分匹配(PSM)平衡混杂因素。采用 Kaplan-Meier 法和 Cox 比例风险回归比较患者的总生存率(OS)。
经过最佳匹配,从每个治疗组筛选出 907 例患者。Kaplan-Meier 法和多变量分析显示,与单纯手术或 CRT/RT 治疗相比,接受手术加 aCRT/CT 治疗的患者 OS 明显更长,即使在 PSM 后也是如此。然而,在分层分析原发部位、T 分期、N 分期和保险状况的治疗效果时,检测到显著的交互作用(所有 P<0.05)。具体而言,手术加 aCRT/CT 显著改善了声门上、T4a 和 N+肿瘤患者的 OS(所有 P<0.001),而对于声门和 T3 肿瘤以及 N0 肿瘤患者,三种治疗方法的 OS 率相同(所有 P>0.05)。此外,声门上肿瘤的预后较声门部位差。
本研究表明,对于 T4a 肿瘤患者,手术加 aCRT/RT 是首选的初始治疗方法,而对于 T3 肿瘤患者,可以采用手术治疗(如果存在 N+,则加 aCRT/RT)或根治性 CRT/RT 以实现喉保留。对于晚期声门上癌,应强调更强化的治疗。